Benzyl phenyl ether compound containing benzofuran and benzothiophene as well as preparation method and application thereof

By developing novel benzylphenylene ether compounds as small molecule inhibitors of the PD-1/PD-L1 signaling pathway, the defects of existing antibodies in tumor treatment were solved and efficient PD-1/PD-L1 binding resistance was achieved. It has demonstrated low cytotoxicity and high inhibition rate, with wide market application and development prospects.

CN118908922APending Publication Date: 2024-11-08GUANGXI UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310509282.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing PD-1/PD-L1 monoclonal antibodies have problems such as inability to take orally, low bioavailability, high production costs and many immune-related adverse reactions in tumor treatment. The tumor immune microenvironment is complex and unknown, which limits its development. and application.

Method used

A novel benzylphenylene ether compound was developed, which conforms to the specific general formula. It is a small molecule inhibitor of the PD-1/PD-L1 signaling pathway. It is prepared through reasonable design and commonly used organic synthesis reaction methods. It has novel structure and simple preparation. and exhibits low cytotoxicity and high inhibition of PD-1/PD-L1 binding.

Benefits of technology

Achieve a high rate of inhibition of PD-1/PD-L1 binding blockade, and has the potential to become a new and efficient tumor treatment drug, suitable for immunomodulation of various related diseases, showing a lower rate than the positive drug BMS-202 Cytotoxicity, with wide market application and development prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004216734310000021
    Figure BDA0004216734310000021
  • Figure BDA0004216734310000031
    Figure BDA0004216734310000031
  • Figure BDA0004216734310000032
    Figure BDA0004216734310000032
Patent Text Reader

Abstract

The invention discloses a benzyl phenyl ether compound, which is a compound conforming to a general formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof, in addition, the inventor also establishes a preparation method of the corresponding compound, raw materials and reagents involved in the reaction are cheap and easy to obtain, and the used reaction method is a common reaction for organic synthesis. Therefore, the compound has the characteristics of novel structure, simplicity in preparation and the like. The compound disclosed by the invention shows lower cytotoxicity than a positive drug BMS-202 on a cellular level; the highest inhibition rate of the compound for blocking the combination of PD-L1 and PD-1 reaches 49%, and the compound has the potential of being researched, developed and transformed into novel, efficient, economical, simple and convenient medicines for related diseases, has wide market application and development prospects, and has broad application prospects. The compound can be used for preparing immunoregulation medicines for treating diseases related to PD-1 / PD-L1 signal channels, such as malignant tumors, autoimmune diseases, organ transplantation rejection, infectious diseases or inflammation related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and in particular relates to benzyl phenyl ether compounds containing benzofuran and benzothiophene, and a preparation method and application thereof. Background Art

[0002] Programmed death receptor 1 (PD-1), also known as CD279, is a member of the immunoglobulin superfamily and a major negative regulator involved in T cell immune regulation. PD-1 expression can be observed in activated monocytes, tumor infiltrating lymphocytes (TILs), dendritic cells (DCs), natural killer cells (NK), T cells, and B cells. Programmed death receptor ligand-1 (PD-L1, also known as B7-H1 and CD274) is the ligand of PD-1, which is widely expressed in antigen-presenting cells and parenchymal cells and vascular endothelial cells of peripheral tissues, and is upregulated by inflammatory cytokines. After binding to its physiological ligand, PD-1 can recruit tyrosine phosphatase SHP-2. SHP-2 affects downstream pathways by dephosphorylating kinases involved in T cell immune activation, such as phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), phospholipase Cγ (PLCγ), extracellular signal-regulated kinase (ERK), etc., while also inactivating Zap70, the main integrator of T cell receptor (TCR)-mediated signals, to inhibit immune activity. PD-L1 can also bind to the co-stimulatory receptor CD80 to affect T cell regulation.

[0003] Under normal circumstances, the PD-1 / PD-L1 signaling pathway exists to control the degree of inflammation at the site of antigen expression and ensure that normal tissues are not damaged. When T cells recognize antigens expressed on target cells, they produce inflammatory cytokines that trigger the inflammatory process. These cytokines induce PD-L1 expression in tissues by activating the PD-1 protein in T cells. The combination of PD-1 and PD-L1 prevents the continuous activation of T cells, thereby achieving reasonable control of the inflammatory response of the immune system. This protein-receptor binding mode maintains the homeostasis of the immune system. In the tumor microenvironment, tumor cells can inactivate the immune response by interfering with the signal transduction of immune cells by overexpressing PD-L1. Continuous activation of the PD-1 / PD-L1 signaling pathway causes suppression of immune toxic cells and weakens the killing of cancer cells by T cells, thereby causing tumor cells to escape immune surveillance through this signal axis.

[0004] Monoclonal antibodies targeting PD-1 / PD-L1 are widely used in many solid tumors and hematological malignancies due to their efficacy and favorable toxicity characteristics, bringing breakthrough progress to immunotherapy. Currently, more than 7 PD-1 or PD-L1 monoclonal antibodies have been approved by the FDA for a variety of tumor types, including Merkel cell carcinoma (MCC), melanoma, head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer (NSCLC). Although immunotherapy targeting the PD-1 / PD-L1 pathway has completely changed the treatment prospects of different cancers, the PD-1 / PD-L1 inhibitors currently sold on the market and used in clinical practice are all PD-1 / PD-L1 monoclonal antibodies. As biological macromolecules, monoclonal antibodies have many unavoidable defects, such as inability to be taken orally, low in vivo bioavailability, high production costs, and many immune-related adverse reactions. In addition, the complex and unknown immune tolerance mechanism in the tumor immune microenvironment is also a key factor limiting the development of such drugs, and only 20%-30% of tumor patients benefit from them.

[0005] PD-1 / PD-L1 small molecule inhibitors can serve as substitutes for PD-1 / PD-L1 monoclonal antibodies. CA-170, an oral bioavailable dual-target small molecule inhibitor targeting PD-L1 / L2 and VISTA immunoglobulin domains jointly developed by Aurigene and Curis in 2016, is the first PD-1 / PD-L1 small molecule inhibitor to enter clinical trials. Following the pace of CA-170, PD-1 / PD-L1 small molecule inhibitors such as INCB-086550, GS-4224, MAX-10181, IMH-010 and AN-4005 have also entered the clinical trial stage one after another. As a pharmaceutical company, Bristol-Myers Squibb has driven the development of the entire PD-1 / PD-L1 inhibitor. In 2015, BMS first announced the structure of its biphenyl skeleton-based phenyl benzyl ether PD-1 / PD-L1 small molecule inhibitor through a patent (WO2015034820) and measured the blocking activity of the compound on PD-1 / PD-L1 by homogenous time-resolved fluorescence (HTRF) method. Among them, the most active compounds are BMS-8 and BMS-202, IC 50 146nM and 18nM respectively. In the following years, PD-1 / PD-L1 small molecule inhibitors developed by different pharmaceutical companies and academic institutions have been disclosed one after another. Despite this, no small molecule inhibitor has yet entered clinical application. Among the small molecule inhibitors with a biphenyl skeleton, only the earliest developed BMS-202 has entered the preclinical research stage. The development of PD-1 / PD-L1 small molecule inhibitors is still in its infancy. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a benzyl phenyl ether compound containing benzofuran and benzothiophene which has a novel structure, is simple to prepare and has good effects, and a preparation method and application thereof.

[0007] In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0008] Benzyl phenyl ether compounds are compounds conforming to the following general formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or hydrates thereof;

[0009]

[0010] in,

[0011] X is O, S;

[0012] R 1 It is H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl, or C1-10 saturated / unsaturated alkyl or heteroalkyl, C3-10 saturated / unsaturated cycloalkyl or heterocycloalkyl substituted with H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl;

[0013] R 2 It is H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl, or C1-10 saturated / unsaturated alkyl or heteroalkyl, C3-10 saturated / unsaturated cycloalkyl or heterocycloalkyl substituted with H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl;

[0014] R 3 is C1-10 alkyl or heteroalkyl, C3-10 cycloalkyl or heterocycloalkyl, benzene ring, condensed aromatic ring, aromatic heterocycle, benzoheterocycle, aromatic heterocycle-conjugated cycloalkyl;

[0015] R 4 Any of the following groups:

[0016]

[0017] The above-mentioned benzyl phenyl ether compound is one of the following compounds YXQ-1 to YXQ-31:

[0018]

[0019]

[0020] Pharmaceutically acceptable salts include salts of the compound of formula I with acids, metal ions, pharmaceutically acceptable amines, ammonium ions or choline.

[0021] The acid is galactaric acid, D-glucuronic acid, glycerophosphoric acid, hippuric acid, isethionic acid, lactobionic acid, maleic acid, 1,5-naphthalenedisulfonic acid, naphthalene-2-sulfonic acid, pivalic acid, terephthalic acid, thiocyanic acid, bile acid, n-dodecylsulfuric acid, benzenesulfonic acid, citric acid, D-glucose, glycolic acid, lactic acid, malic acid, malonic acid, mandelic acid, phosphoric acid, propionic acid, hydrochloric acid, sulfuric acid, tartaric acid, succinic acid, formic acid, hydroiodic acid, hydrobromic acid, methanesulfonic acid, nicotinic acid, nitric acid, orotic acid, oxalic acid, picric acid , L-pyroglutamic acid, saccharinic acid, salicylic acid, gentisic acid, p-toluenesulfonic acid, valeric acid, palmitic acid, sebacic acid, stearic acid, lauric acid, acetic acid, adipic acid, carbonic acid, 4-benzenesulfonic acid, ethanedisulfonic acid, ethylsuccinic acid, fumaric acid, 3-hydroxynaphthalene-2-carboxylic acid, 1-hydroxynaphthalene-2-carboxylic acid, oleic acid, undecylenic acid, ascorbic acid, camphoric acid, camphorsulfonic acid, dichloroacetic acid, ethanesulfonic acid; the metal ions are sodium, potassium, and calcium ions; the pharmaceutically acceptable amines are ethylenediamine and tromethamine.

[0022] Application of the above-mentioned benzyl phenyl ether compounds in the preparation of drugs for diseases related to the PD-1 / PD-L1 signaling pathway.

[0023] Diseases related to the PD-1 / PD-L1 signaling pathway include malignant tumors, autoimmune diseases, organ transplant rejection, infectious diseases, and inflammatory diseases; the drugs are PD-1 / PD-L1 inhibitors.

[0024] The malignant tumors were breast cancer (HCC1937), cervical cancer (HeLa), liver cancer (HepG2), non-small cell carcinoma, ovarian cancer, Merkel cell carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, bladder cancer, colorectal cancer, pancreatic cancer, peritoneal cancer, glioma, glioblastoma, melanoma, prostate cancer, lymphoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, gastrointestinal stromal tumor, thyroid cancer, bile duct cancer, endometrial cancer, fallopian tube cancer, renal cell carcinoma, anaplastic large cell lymphoma, acute myeloid leukemia and multiple leukemia. Myeloma; autoimmune diseases include chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, systemic lupus erythematosus, autoimmune hemolytic anemia, rheumatoid arthritis, ulcerative colitis and Crohn's disease; organ transplantation includes liver transplantation, bone marrow transplantation, kidney transplantation and heart transplantation; infectious diseases include bacterial and viral infections; inflammatory diseases include acute idiopathic polyneuritis, non-alcoholic fatty hepatitis, pneumonia, emphysema, rhinitis, myocarditis, neurodermatitis, tracheitis, respiratory distress syndrome and chronic obstructive pulmonary disease.

[0025] The preparation method of the above-mentioned benzyl phenyl ether compound is carried out according to the following reaction scheme:

[0026]

[0027] wherein Y is fluorine, chlorine, bromine, iodine, methanesulfonate, p-toluenesulfonate or trifluoromethanesulfonate.

[0028] The above preparation method comprises the following steps:

[0029] <1> Compound (II) is subjected to formylation reaction under the action of Lewis acid to prepare compound (III);

[0030] <2> Compound (IV) is prepared by reduction reaction of compound (III);

[0031] <3> The compound (V) is prepared by halogenation reaction of the compound (IV);

[0032] <4> Compound (VII) is prepared by reacting compound (V) with compound (VI) under alkaline conditions through a nucleophilic substitution reaction;

[0033] <5> Compound (X) is prepared by reacting compound (VII) with compound (VIII) under alkaline conditions through a nucleophilic substitution reaction;

[0034] <6> Compound (IX) can be prepared by reductive amination reaction of compound (X) with compound (IX).

[0035] step <1> In the method, the Lewis acid is anhydrous SnCl4, TiCl4, AlCl3, and POCl3; the formylation reagent used is 1,1-dichloromethyl methyl ether and N,N-dimethyl methyl ether; the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, and dimethyl sulfoxide; and the reaction temperature is room temperature;

[0036] step <2> In the reduction reaction, the reducing agent used is sodium borohydride or potassium borohydride, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is -20°C to room temperature;

[0037] step <3> In the halogenation reaction, the halogenating agent used is PBr3, CBr4, HBr, SOCl2, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is -20°C to room temperature;

[0038] step <4> In the nucleophilic substitution reaction, the base used is sodium cyanide, potassium carbonate, sodium carbonate, cesium carbonate, sodium bicarbonate, triethylamine, diisopropylethylamine, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is 60°C-80°C;

[0039] step <5> In the nucleophilic substitution reaction, the base used is sodium cyanide, potassium carbonate, sodium carbonate, cesium carbonate, sodium bicarbonate, triethylamine, diisopropylethylamine, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is 60°C-80°C;

[0040] step <6> In the reductive amination reaction, the reducing agent used is sodium borohydride, sodium triacetoxyborohydride or cyanoborohydride, and the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide or a combination thereof; the reaction temperature is room temperature.

[0041] In view of the problems existing in the current PD-1 / PD-L1 inhibitors, the inventors have obtained benzyl phenyl ether compounds through rational design, which are compounds conforming to the general formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or hydrates thereof;

[0042]

[0043] In addition, the inventors have also established a method for preparing the corresponding compounds. The raw materials and reagents involved in the reaction are cheap and easy to obtain, and the reaction method used is a common reaction in organic synthesis. Therefore, this type of compound has the characteristics of novel structure and simple preparation. Preliminary biological activity evaluation and toxicity tests on this type of compound showed that the compounds of the present invention showed lower cytotoxicity than the positive drug BMS-202 at the cellular level; the PD-1 / PD-L1 binding blocking experiment showed that the inhibition rate of the compounds of the present invention blocking the binding of PD-L1 and PD-1 reached up to 49%, and it has the potential to be developed and transformed into a new, efficient and economical and easy-to-prepare drug for related diseases (targeting the PD-1 / PD-L1 pathway), and has a wide range of market applications and development prospects. It can be used to prepare immunomodulatory drugs for the treatment of diseases related to the PD-1 / PD-L1 signaling pathway, such as malignant tumors, autoimmune diseases, organ transplant rejection, infectious diseases or inflammatory-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 It is the reaction scheme of compounds YXQ-1 to YXQ-15 in Examples 1-15.

[0045] Figure 2 This is the reaction scheme of compound YXQ-16 in Example 16.

[0046] Figure 3 This is the reaction scheme of compound YXQ-17 in Example 17.

[0047] Figure 4 It is the reaction scheme of compounds YXQ-18 to YXQ-22 in Examples 18-22.

[0048] Figure 5 It is the reaction scheme of compounds YXQ-23 to YXQ-27 in Examples 23-27.

[0049] Figure 6 It is the reaction scheme of compounds YXQ-28 to YXQ-30 in Examples 28-30.

[0050] Figure 7 This is the reaction scheme of compound YXQ-31 in Example 31. DETAILED DESCRIPTION

[0051] To further explain how to implement the present invention, the present invention will be further described below in conjunction with specific embodiments. Wherein, unless otherwise specified, the raw materials used are commercially available products.

[0052] Example 1 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(2-hydroxyethyl)(methyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-1)

[0053] Preparation of compound (III-1)

[0054] Weigh dibenzofuran (1g), add dichloromethane (20mL) to dissolve, and stir at room temperature for ten minutes. Add anhydrous SnCl4 (1mL) to the above system, then slowly add dichloromethyl methyl ether (0.8mL) dropwise, and monitor the reaction progress by TLC. After the reaction is completed, quench the reaction with 1mol / LHCl, then wash with saturated NaHCO3 and saturated NaCl solution in turn, extract with dichloromethane (50mL) several times, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder, mix well and prepare samples, separate and purify the crude product by silica gel column chromatography, and obtain yellow solid compound (III-1) (0.94g, 80%) after purification. After detection and analysis, its spectral data are as follows:

[0055] 1 H NMR(600MHz,Chloroform-d)δ10.03(s,1H),8.40(d,J=1.6Hz,1H),7.95–7.84(m,2H), 7.59(d,J=8.5Hz,1H),7.52(d,J=8.2Hz,1H),7.49–7.41(m,1H),7.33(t,J=7.5Hz,1H).

[0056] Preparation of compound (IV-1)

[0057] Weigh compound (III-1) (420 mg) into a 100 mL eggplant-shaped bottle, add methanol (8 mL) to dissolve and stir at 0°C for 15 minutes, then slowly add sodium borohydride (50 mg), and continue to react at 0°C for 30 minutes. After the reaction is completed, pour ice water (10 mL) into the reaction solution and filter to collect a yellow solid compound (IV-1) (450 mg, 100%) (the crude product can be directly used in the next step without further purification). After detection and analysis, its spectral data are as follows: 1H NMR(600MHz,Chloroform-d)δ7.91(d,J=1.7Hz,1H),7.88(dd,J=7.7,1.2Hz,1H),7.49 (dd,J=13.0,8.3Hz,2H),7.43–7.36(m,2H),7.28(td,J=7.6,1.0Hz,1H),4.78(s,2H).

[0058] Preparation of compound (V-1)

[0059] Weigh compound (Ⅳ-1) (200 mg) into a 50 ml sealed eggplant-shaped bottle, add anhydrous dichloromethane (8 mL) to dissolve, stir at -10 ° C for 30 minutes, slowly add PBr3 (75 μL), and continue to react until there is no raw material left. After the reaction is completed, add water (10 mL) to quench the reaction, and wash with saturated NaHCO3 and saturated NaCl solutions in turn, extract with dichloromethane (30 mL) (repeat 3-5 times), and collect the organic phase. The collected crude product is separated and purified by silica gel chromatography using n-hexane as the eluent to obtain a white powder compound (Ⅴ-1) (125 mg, 47.45%). After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.91(d,J=1.8Hz,1H),7.86(m,1H),7.49(m,1H), 7.46(d,J=8.4Hz,1H),7.43–7.37(m,2H),7.28(m,1H),4.61(d,J=16.9Hz,2H).

[0060] Preparation of compound (VII-1)

[0061] Weigh 2,4-dihydroxybenzaldehyde (317 mg) and anhydrous K2CO3 (529 mg), add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 30 minutes, then slowly add compound (Ⅴ-1) (500 mg) and continue to react for 3 hours. After the reaction is completed, remove the acetonitrile solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) several times, and dry the organic phase with anhydrous sodium sulfate and filter to obtain a crude product. The crude product is separated by silica gel chromatography to obtain a light yellow powder compound (Ⅶ-1) (410 mg, 67.26%). After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ11.04(s,1H),10.02(s,1H),8.27(d,J=2.0Hz,1H),8.18(d,J=7.8Hz,1H),7.74(dd,J=12.8,8.4Hz,2H),7.67– 7.61(m,2H),7.55(ddd,J=8.4,7.3,1.3Hz,1H),7.43(t,J=7.5Hz,1H),6.70(dd,J=8.7,2.3Hz,1H),6.63(d,J=2.4Hz,1H),5.33(s,2H).

[0062] Preparation of compound (X-1)

[0063] Weigh compound (VII-1) (356 mg) and anhydrous K2CO3 (309 mg) into a 100 ml eggplant-shaped bottle, add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 15 minutes, then add 3-bromomethylbenzonitrile (263 mg) and continue to react for 1 hour. After the reaction is completed, remove the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) for several times, dry the organic phase over anhydrous sodium sulfate, and filter to obtain a crude product. Then, purify the crude product by beating in an ice bath with a mixed solvent of ethyl acetate / petroleum ether = 15 / 1, and filter to obtain a milky white solid compound (X-1) (320 mg, 66.01%).

[0064] Preparation of compound YXQ-1

[0065] Weigh compound (X-1) (100 mg) and dissolve it in a mixed solvent of dichloromethane and methanol (4:1, 5 mL), add N-methyl-2-hydroxyethylamine (163 μL) and stir at room temperature for 10 minutes, then add two drops of glacial acetic acid, react at room temperature for 6-8 hours, then add sodium triacetoxyborohydride (195 mg) and continue to react for 12 hours to stop the reaction, evaporate the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 ml) several times, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder and mix well to prepare a sample, separate and purify the crude product by silica gel column chromatography to obtain a light yellow viscous compound YXQ-1 (52 mg, 45.76%). After detection and analysis, its spectral data are as follows: 1H NMR(600MHz,Chloroform-d)δ7.96–7.91(m,1H),7.88(d,J=7.5Hz,1H),7.62(s, 1H),7.53(dd,J=25.5,8.3Hz,4H),7.44–7.37(m,3H),7.32–7.24(m,2H),6.60(d d,J=8.4,2.3Hz,1H),6.50(d,J=2.3Hz,1H),5.11(s,2H),5.03(s,2H),3.80(d,J =5.4Hz,2H),3.66(t,J=5.1Hz,2H),2.75(t,J=5.1Hz,2H),2.40(s,3H).HRMS(ESI + )m / z:493.2178[M+H] +

[0066] Example 2 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(3-hydroxypropyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-2)

[0067] Referring to the method of Example 1, 3-amino-1-propanol was used to replace N-methyl-2-hydroxyethylamine to obtain a yellow viscous compound YXQ-2. After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, DMSO-d6) δ8.24(d,J=1.7Hz,1H),8.20–8.13(m,1H),7.94(d,J=1.8Hz,1H),7.81(tt,J=8 .0,1.4Hz,2H),7.75–7.69(m,2H),7.64–7.58(m,2H),7.55(ddd,J=8.4,7.2,1.4Hz,1H),7.45–7.39(m ,1H),7.28(d,J=8.3Hz,1H),6.79(d,J=2.4Hz,1H),6.69(ddd,J=10.2,8.2,2.9Hz,1H),5.25(s,2H),5 .22(s,2H),3.79(s,2H),3.45(t,J=6.1Hz,2H),2.68(t,J=7.1Hz,2H),1.62(p,J=6.6Hz,2H).HRMS(ESI + )m / z:493.2188[M+H] +

[0068] Example 3 Preparation of [({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(2-hydroxyethyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-3)

[0069] Referring to the method of Example 1, ethanolamine was used to replace N-methyl-2-hydroxyethylamine to obtain a light yellow solid compound YXQ-3. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.91(d,J=1.7Hz,1H),7.88–7.85(m,1H),7.63(q,J=2 .2,1.7Hz,1H),7.58(dt,J=7.8,1.4Hz,1H),7.54–7.47(m,3H),7.44–7.38(m,3H),7. 31–7.26(m,1H),7.21(d,J=8.3Hz,1H),6.60–6.55(m,1H),6.48(d,J=2.3Hz,1H),5. 08(s,2H),5.05(s,2H),3.95(s,2H),3.68–3.62(m,2H),2.85–2.78(m,2H).HRMS(ESI + )m / z:479.2045[M+H] +

[0070] Example 4 Preparation of 3-{[(2-{[(1,3-dihydroxypropan-2-yl)amino]methyl}-5-[({3-[(1Z)-ethylidene]-2-methylidene-1-benzofuran-5-yl}methyl)oxy]phenyl)oxy]methyl}benzene-1-carbonitrile (YXQ-4)

[0071] Referring to the method of Example 1, serinol was used to replace N-methyl-2-hydroxyethylamine to obtain a light yellow solid compound YXQ-4. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.24(d,J=1.7Hz,1H),8.16(ddd,J=10.2,7.7,1.7Hz,1H),7.95(d,J=1.7Hz,1H),7.84 (dt,J=7.9,1.5Hz,1H),7.80(dt,J=7.8,1.5Hz,1H),7.72(d,J=8.3Hz,2H),7.63–7.57(m,2H),7.55(tt,J=7.3, 1.4Hz,1H),7.42(tt,J=7.4,1.8Hz,1H),7.33–7.27(m,1H),6.78(d,J=2.4Hz,1H),6.69(dd,J=8.3,2.3Hz,1H) ,5.76(s,1H),5.24(s,2H),5.21(s,2H),3.49–3.47(m,2H),3.44–3.41(m,2H),2.70(q,J=5.7Hz,1H).HRMS(ESI + )m / z:509.2154[M+H] +

[0072] Example 5 Preparation of N-[(2-{[(3-cyanophenyl)methyl]oxy}-4-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]phenyl)methyl]-D-serine ethyl ester (YXQ-5)

[0073] Referring to the method of Example 1, D-serine ethyl ester hydrochloride was used to replace N-methyl-2-hydroxyethylamine to obtain a yellow solid compound YXQ-5. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.24(d,J=1.7Hz,1H),8.17(t,J=6.2Hz,1H),7.93(s,1H),7.82–7.78(m,2H),7.72(d,J=8.3H z,2H),7.62–7.57(m,2H),7.57–7.52(m,1H),7.42(t,J=7.5Hz,1H),7.21(d,J=8.3Hz,1H),6.75(d,J=2.4Hz,1H),6.66 (dd,J=8.3,2.3Hz,1H),5.23(s,2H),5.19(d,J=2.6Hz,2H),4.81(t,J=5.7Hz,1H),4.01(qd,J=7.1,2.6Hz,2H),3.74(d ,J=13.4Hz,1H),3.60(d,J=13.3Hz,1H),3.54(t,J=5.5Hz,2H),3.24(t,J=5.4Hz,1H),1.12(t,J=7.1Hz,3H).HRMS(ESI + )m / z:551.2255[M+H] +

[0074] Example 6 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-(1,4-oxazacyclohexane-4-ylmethyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-6)

[0075] Referring to the method of Example 1, N-methyl-2-hydroxyethylamine was replaced with morpholine to obtain a light yellow viscous compound YXQ-6. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,DMSO-d6)δ8.24(d,J=1.7Hz,1H),8.16(t,J=8.4Hz,1H),7.93(s,1H) ,7.80(dd,J=21.3,7.9Hz,2H),7.72(d,J=8.4Hz,2H),7.64–7.58(m,2H),7.57–7.5 2(m,1H),7.42(t,J=7.5Hz,1H),7.20(d,J=8.3Hz,1H),6.78(d,J=2.4Hz,1H),6.70 –6.64(m,1H),5.22(d,J=3.9Hz,4H),3.57(t,J=4.6Hz,4H),2.36(s,4H).HRMS(ESI + )m / z:505.2203[M+H] +

[0076] Example 7 Preparation of 3-{[(2-{[(2-aminoethyl)amino]methyl}-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]phenyl)oxy]methyl}benzene-1-carbonitrile (YXQ-7)

[0077] Referring to the method of Example 1, ethylenediamine was used to replace N-methyl-2-hydroxyethylamine to obtain a yellow solid compound YXQ-7. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.93(s,1H),7.88(d,J=7.5Hz,1H),7.65(d,J=28.1Hz, 1H),7.57(d,J=7.8Hz,1H),7.55–7.46(m,3H),7.46–7.34(m,3H),7.29(t,J=7.4Hz,1 H),7.21(d,J=8.7Hz,1H),6.56(dd,J=22.2,8.3Hz,1H),6.48(d,J=2.1Hz,1H),5.10( s,2H),5.04(s,2H),3.92(s,2H),2.95–2.92(m,2H),2.81(d,J=5.7Hz,2H).HRMS(ESI + )m / z:478.2188[M+H] +

[0078] Example 8 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-({[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-8)

[0079] Referring to the method of Example 1, trishydroxymethylaminomethane was used to replace N-methyl-2-hydroxyethylamine to obtain a milky white solid compound YXQ-8. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.24(d,J=1.7Hz,1H),8.16(t,J=9.0Hz,1H),7.98(s,1H),7. 87(d,J=7.9Hz,1H),7.79(d,J=7.7Hz,1H),7.74–7.67(m,2H),7.62–7.57(m,2H),7.5 7–7.51(m,1H),7.43(t,J=7.5Hz,1H),7.33(d,J=8.4Hz,1H),6.80(d,J=2.4Hz,1H),6 .74–6.67(m,1H),5.32–5.25(m,2H),5.23(s,2H),4.05(s,2H),3.53(s,6H).HRMS(ESI + )m / z:539.2250[M+H] +

[0080] Example 9 Preparation of 3-{[(2-{[(3-amino-2-hydroxypropyl)amino]methyl}-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]phenyl)oxy]methyl}benzene-1-carbonitrile (YXQ-9)

[0081] Referring to the method of Example 1, 1,3-diamino-2-hydroxypropane was used to replace N-methyl-2-hydroxyethylamine to obtain a yellow solid compound YXQ-9. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.96–7.87(m,1H),7.85(d,J=7.7Hz,1H),7.62(s,1 H),7.57–7.44(m,3H),7.43–7.34(m,2H),7.27(d,J=14.9Hz,1H),7.19(s,3H),6.5 7–6.51(m,1H),6.46(d,J=2.2Hz,1H),5.06(s,2H),5.01(s,2H),3.95(d,J=13.3H z,1H),3.86(d,J=13.2Hz,1H),2.95–2.80(m,2H),2.66(d,J=9.4Hz,2H).HRMS(ESI + )m / z:508.2297[M+H] +

[0082] Example 10 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-(5-methyl-2,5-diazahexan-1-yl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-10)

[0083] Referring to the method of Example 1, N-methyl-2-hydroxyethylamine was replaced with N,N-dimethylethylenediamine to obtain a yellow viscous compound YXQ-10. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,DMSO-d6)δ8.24(d,J=1.7Hz,1H),8.19–8.15(m,1H),7.94(d,J=1.8Hz,1H),7.85– 7.78(m,2H),7.75–7.69(m,2H),7.64–7.59(m,2H),7.57–7.52(m,1H),7.42(tt,J=7.5,1.7Hz, 1H),7.24(dd,J=8.4,5.0Hz,1H),6.79(d,J=2.4Hz,1H),6.69(dt,J=8.3,2.5Hz,1H),5.22(d,J =26.1Hz,4H),3.74(s,2H),2.62(t,J=6.2Hz,2H),2.36(t,J=6.2Hz,2H),2.08(s,6H).HRMS(ESI + )m / z:506.2508[M+H] +

[0084] Example 11 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-({[2-(1,4-oxazacyclohexane-4-yl)ethyl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-11)

[0085] Referring to the method of Example 1, N-(2-aminoethyl)-morpholine was used to replace N-methyl-2-hydroxyethylamine to obtain a yellow viscous compound YXQ-11. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.23(d,J=1.7Hz,1H),8.14(t,J=8.3Hz,1H),7.94(d,J=2.3Hz,1H),7.81(dd,J= 13.5,7.9Hz,2H),7.70(t,J=8.7Hz,2H),7.60(t,J=7.7Hz,2H),7.54(ddd,J=8.4,7.2,1.3Hz,1H),7.41(t ,J=7.2Hz,1H),7.28(d,J=8.3Hz,1H),6.80(d,J=2.3Hz,1H),6.72–6.65(m,1H),5.24(s,2H),5.21(s,2H) ,3.82(s,2H),3.47(t,J=4.6Hz,4H),2.69(t,J=6.3Hz,2H),2.40(t,J=6.3Hz,2H),2.25(s,4H).HRMS(ESI + )m / z:548.2627[M+H] +

[0086] Example 12 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-({[(1r,4r)-4-hydroxycyclohexyl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-12)

[0087] Referring to the method of Example 1, N-methyl-2-hydroxyethylamine was replaced with trans-p-aminocyclohexanol to obtain a yellow solid compound YXQ-12. After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, DMSO-d6) δ8.24(d,J=1.7Hz,1H),8.16(ddd,J=10.0,7.7,1.4Hz,1H),7.94(d,J=1.7Hz,1H),7.8 5–7.76(m,2H),7.76–7.69(m,2H),7.61(ddd,J=7.8,4.4,2.7Hz,2H),7.58–7.51(m,1H),7.42(t,J=7.5Hz,1H ),7.24(d,J=8.3Hz,1H),6.77(d,J=2.3Hz,1H),6.70–6.63(m,1H),5.22(d,J=27.0Hz,4H),3.35(dt,J=10.2, 4.2Hz,1H),2.35(ddt,J=10.0,7.2,3.8Hz,1H),1.83(s,2H),1.80–1.71(m,2H),1.14–1.00(m,4H).HRMS(ESI +)m / z:533.2499[M+H] +

[0088] Example 13 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-(tetrahydro-1H-pyrrol-1-ylmethyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-13)

[0089] Referring to the method of Example 1, cyclopentylamine was used to replace N-methyl-2-hydroxyethylamine to obtain a brown viscous compound YXQ-13. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.25 (d, J = 1.7 Hz, 1H), 8.20-8.13 (m, 1H), 7.95 (d, J = 1.9 Hz, 1H), 7.81 (dt, J = 7.9, 2.1 Hz, 2H), 7.72 (d, J = 8.2 Hz, 2H), 7.61 (ddd, J = 7.8, 4.5, 2.7 Hz, 2H), 7.57-7.50 (m, 1H), 7.42 (t, J = 7.4 Hz, 1H), 7.26 (d, J = 8. 3Hz,1H),6.79(d,J=2.3Hz,1H),6.68(dd,J=8.3,2.4Hz,1H),5.25(s,2H),5.20(s,2H),3.71(s,2H),3.07(p,J=6.5 Hz,1H),1.72(dt,J=12.9,6.7Hz,2H),1.62–1.57(m,2H),1.52–1.48(m,2H),1.37(dq,J=12.2,6.0Hz,2H).HRMS(ESI + )m / z:503.2407[M+H] +

[0090] Example 14 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-(piperidin-1-ylmethyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-14)

[0091] Referring to the method of Example 1, cyclohexylamine was used to replace N-methyl-2-hydroxyethylamine to obtain a brown solid compound YXQ-14. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.25(d,J=1.7Hz,1H),8.20–8.13(m,1H),7.98(d,J=1.7Hz,1H),7.82(dt,J=8.0,1.6Hz,2H) ,7.76–7.68(m,2H),7.61(ddd,J=7.8,4.5,2.7Hz,2H),7.55(ddd,J=8.4,7.3,1.4Hz,1H),7.46–7.40(m,1H),7.32(d ,J=8.3Hz,1H),6.82(d,J=2.3Hz,1H),6.73–6.66(m,1H),5.27(s,2H),5.20(s,2H),3.85(s,2H),2.60(d,J=10.2Hz, 1H),1.66(dt,J=12.8,3.5Hz,2H),1.54(d,J=11.4Hz,1H),1.23(s,1H),1.12(pd,J=14.0,13.2,7.7Hz,6H).HRMS(ESI + )m / z:517.2585[M+H] +

[0092] Example 15 Preparation of N-[(2-{[(3-cyanophenyl)methyl]oxy}-4-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]phenyl)methyl]-L-serine ethyl ester (YXQ-15)

[0093] Referring to the method of Example 1, L-serine ethyl ester hydrochloride was used to replace N-methyl-2-hydroxyethylamine to obtain a yellow viscous compound YXQ-15. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.31–8.21(m,1H),8.20–8.13(m,1H),7.93(d,J=1.7Hz,1H),7.85–7.76(m,2H),7.76–7.68(m,2H ),7.60(t,J=7.7Hz,2H),7.57–7.50(m,1H),7.42(t,J=7.5Hz,1H),7.22(d,J=8.3Hz,1H),6.76(d,J=2.4Hz,1H),6.70–6. 63(m,1H),5.29–5.21(m,2H),5.19(d,J=2.6Hz,2H),4.82(t,J=5.8Hz,1H),4.02(pd,J=7.1,6.4,2.9Hz,2H),3.78–3.70( m,1H),3.61(d,J=13.4Hz,1H),3.55(q,J=3.6,2.4Hz,2H),3.24(t,J=5.3Hz,1H),1.15(dt,J=31.8,7.1Hz,3H).HRMS(ESI + )m / z:551.2260[M+H] +

[0094] Example 16 Preparation of 4-[({5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(2-hydroxyethyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-16)

[0095] Preparation of compound (X-2)

[0096] Weigh compound (VII-1) (200 mg) and anhydrous K2CO3 (174 mg) in a 100 ml eggplant-shaped bottle, add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 15 minutes, then add p-cyanobenzyl bromide (135 mg) and continue to react for 1 hour. After the reaction is completed, remove the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) for several times, and dry the organic phase over anhydrous sodium sulfate and filter to obtain a crude product. The crude product is separated and purified by silica gel chromatography to obtain a milky white solid compound (X-2) (246 mg, 90.44%). After detection and analysis, its spectral data are as follows: 1H NMR(600MHz,DMSO-d6)δ10.29(s,1H),8.27(d,J=1.7Hz,1H),8.17(dd,J=7.8,1.2Hz,1H), 7.87(d,J=1.9Hz,1H),7.86(d,J=1.7Hz,1H),7.75(s,1H),7.73(s,1H),7.72(s,1H),7.71( s,1H),7.69(s,1H),7.63(dd,J=8.5,1.8Hz,1H),7.55(ddd,J=8.4,7.2,1.3Hz,1H),7.45– 7.40(m,1H),6.94(d,J=2.3Hz,1H),6.85(dd,J=8.7,2.2Hz,1H),5.41(s,2H),5.37(s,2H).

[0097] Preparation of compound YXQ-16

[0098] Weigh compound (Ⅹ-2) (200 mg) and dissolve it in a mixed solvent of dichloromethane and methanol (4:1, 5 mL), add ethanolamine (0.28 mL) and stir at room temperature for 10 minutes, then add two drops of glacial acetic acid, react at room temperature for 6-8 hours, then add sodium triacetoxyborohydride (391 mg) and continue to react for 12 hours to stop the reaction, evaporate the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 ml) several times, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder and mix well to prepare a sample, separate and purify the crude product by silica gel column chromatography to obtain a milky white solid compound YXQ-16 (160 mg, 72.46%). After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,DMSO-d6)δ8.24(d,J=1.7Hz,1H),8.16(ddd,J=10.5,7.8,2.0Hz,1H),7.88–7.82( m,2H),7.78–7.69(m,2H),7.69–7.63(m,2H),7.60(dd,J=8.5,1.8Hz,1H),7.55(ddd,J=8.4,7. 2,1.4Hz,1H),7.45–7.39(m,1H),7.26(d,J=8.3Hz,1H),6.76(d,J=2.4Hz,1H),6.70–6.64(m,1 H),5.24(d,J=18.5Hz,4H),3.76(s,2H),3.50(t,J=5.6Hz,2H),2.63(t,J=5.6Hz,2H).HRMS(ESI + )m / z:479.2046[M+H] +

[0099] Example 17 Preparation of 2-[({4-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-methoxyphenyl}methyl)amino]ethan-1-ol (YXQ-17)

[0100] Preparation of compound (X-3)

[0101] Weigh compound (VII-1) (200 mg) and anhydrous K2CO3 (174 mg) in a 100 ml eggplant-shaped bottle, add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 15 minutes, then add iodomethane (0.3 mL) dropwise and continue to react for 1 hour. After the reaction is completed, remove the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) for several times, and dry the organic phase over anhydrous sodium sulfate and filter to obtain a crude product. The crude product is separated and purified by silica gel chromatography to obtain a white solid compound (X-3) (205 mg, 98.08%). After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,DMSO-d6)δ10.20(s,1H),8.30(d,J=1.7Hz,1H),8.18(dd,J=7.8, 1.4Hz,1H),7.77–7.73(m,1H),7.72(d,J=5.9Hz,1H),7.70(d,J=4.0Hz,1H),7. 66(dd,J=8.4,1.8Hz,1H),7.55(ddd,J=8.3,7.2,1.3Hz,1H),7.46–7.41(m,1H) ,6.86(d,J=2.2Hz,1H),6.81(dd,J=8.7,2.2Hz,1H),5.38(s,2H),3.93(s,3H).

[0102] Preparation of compound YXQ-17

[0103] Weigh compound (Ⅹ-3) (200 mg) and dissolve it in a mixed solvent of dichloromethane and methanol (4:1, 5 mL), add ethanolamine (0.36 mL) and stir at room temperature for 10 minutes, then add two drops of glacial acetic acid, react at room temperature for 6-8 hours, then add sodium triacetoxyborohydride (510 mg) and continue to react for 12 hours to stop the reaction, evaporate the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 ml) several times, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder, mix well and prepare samples, separate and purify the crude product by silica gel column chromatography to obtain yellow viscous compound YXQ-17 (145 mg, 63.84%). After detection and analysis, its spectral data are as follows: 1H NMR(600MHz,DMSO-d6)δ8.34–8.24(m,1H),8.21–8.14(m,1H),7.77–7.68(m,2H), 7.63(dd,J=8.4,1.8Hz,1H),7.54(ddd,J=8.4,7.3,1.3Hz,1H),7.42(t,J=7.5Hz, 1H),7.20(d,J=8.3Hz,1H),6.68(d,J=2.4Hz,1H),6.66–6.59(m,1H),5.24(s,2H) ,3.64(s,2H),3.47(d,J=5.7Hz,2H),3.17(s,1H),2.58(t,J=5.7Hz,2H).HRMS(ESI + )m / z:378.1755[M+H] +

[0104] Example 18 Preparation of 3-[({4-chloro-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(2-hydroxyethyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-18)

[0105] Preparation of compound (VII-2)

[0106] Weigh 5-chloro-2,4-dihydroxybenzaldehyde (575 mg) and NaHCO3 (466 mg), add acetonitrile (20 mL) to dissolve, place at 80 ° C and stir for 30 minutes, then slowly add compound (Ⅴ-1) (725 mg) and continue to react for 6 hours. After the reaction is completed, remove the acetonitrile solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) several times, and dry the organic phase with anhydrous sodium sulfate and filter to obtain a crude product. The crude product is separated by silica gel chromatography to obtain a white solid compound (Ⅶ-2) (509 mg, 51.97%). After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, DMSO-d6) δ11.18(s,1H),10.04(s,1H),8.27(d,J=1.8Hz,1H),8.20–8.15(m,1H),7.78(d,J=8.5Hz,1H),7.75–7.72(m,1H ),7.71(s,1H),7.66(dd,J=8.5,1.8Hz,1H),7.56(ddd,J=8.4,7.3,1.4Hz,1H),7.43(td,J=7.5,0.9Hz,1H),6.86(s,1H),5.41(s,2H).

[0107] Preparation of compound (X-4)

[0108] Weigh compound (VII-2) (258 mg) and anhydrous K2CO3 (202 mg) in a 100 ml eggplant-shaped bottle, add acetonitrile (8 mL) to dissolve, place at 80 ° C and stir for 15 minutes, then add 3-bromomethylbenzonitrile (143 mg) and continue to react for 1 hour. After the reaction is completed, remove the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) for several times, and dry the organic phase over anhydrous sodium sulfate and filter to obtain a crude product. Then, purify the crude product by beating in an ice bath with a mixed solvent of ethyl acetate / petroleum ether = 15 / 1, and filter to obtain a white solid compound (X-4) (208 mg, 60.78%). After detection and analysis, its spectral data are as follows: 1 HNMR (600MHz, DMSO-d6) δ10.23(d,J=3.1Hz,1H),8.28(d,J=1.8Hz,1H),8.21–8.14(m,1H),8.04–7. 98(m,1H),7.85(dt,J=8.0,1.5Hz,1H),7.81(dt,J=7.9,1.5Hz,1H),7.77(d,J=8.4Hz,1H),7.74(d,J =4.7Hz,1H),7.73(s,1H),7.66(dd,J=8.4,1.8Hz,1H),7.60(t,J=7.8Hz,1H),7.56(tdd,J=8.4,3.8, 1.4Hz,1H),7.44(td,J=7.5,0.9Hz,1H),7.25(s,1H),5.53(d,J=23.2Hz,2H),5.43(d,J=7.0Hz,2H).

[0109] Preparation of compound YXQ-18

[0110] Weigh compound (Ⅹ-4) (103 mg) and dissolve it in a mixed solvent of dichloromethane and methanol (4:1, 5 mL), add ethanolamine (0.15 mL) and stir at room temperature for 10 minutes, then add two drops of glacial acetic acid, react at room temperature for 6-8 hours, then add sodium triacetoxyborohydride (187 mg) and continue to react for 12 hours to stop the reaction, evaporate the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 ml) several times, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder and mix well to prepare a sample, separate and purify the crude product by silica gel column chromatography to obtain a yellow viscous compound YXQ-18 (68 mg, 60.22%). After detection and analysis, its spectral data are as follows: 1H NMR(600MHz,Chloroform-d)δ7.86(dd,J=15.5,7.9Hz,2H),7.58–7.50(m,2H),7.47(dt,J=11.9,6.5Hz,2H),7.45–7.39(m,2H),7.37(d,J=8.7Hz,1H) ,7.33–7.23(m,3H),6.41(d,J=29.4Hz,1H),5.17(d,J=10.1Hz,2H),4.96( s,2H),3.87(s,2H),3.63(t,J=4.8Hz,2H),2.80(t,J=4.7Hz,2H).HRMS(ESI + )m / z:513.1648[M+H] +

[0111] Example 19 Preparation of 3-[({4-chloro-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(1,3-dihydroxypropan-2-yl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-19)

[0112] Referring to the method of Example 18, ethanolamine was replaced by serinol to obtain a white solid compound YXQ-19. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.95–7.80(m,2H),7.57(d,J=14.1Hz,1H),7.51 (d,J=8.1Hz,1H),7.47(dd,J=11.4,8.0Hz,2H),7.44–7.39(m,2H),7.37(d,J=8 .5Hz,1H),7.32(s,1H),7.31–7.26(m,2H),6.41(d,J=29.3Hz,1H),5.17(d,J=9 .6Hz,2H),4.97(s,2H),3.94(s,2H),3.76–3.50(m,4H),2.83(s,1H).HRMS(ESI + )m / z:543.1752[M+H] +

[0113] Example 20 Preparation of 3-[({4-chloro-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(3-hydroxypropyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-20)

[0114] Referring to the method of Example 18, ethanolamine was replaced by 3-amino-1-propanol to obtain a white solid compound YXQ-20. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.85(d,J=7.5Hz,2H),7.59(s,1H),7.51(dd,J=8 .1,2.8Hz,2H),7.46(d,J=8.4Hz,1H),7.43–7.39(m,3H),7.34(d,J=8.6Hz,1H) ,7.28(q,J=7.2Hz,2H),6.45(s,1H),5.14(s,2H),5.07(s,2H),3.95(s,2H),3. 57(t,J=5.3Hz,2H),2.98(t,J=5.8Hz,2H),1.79(p,J=6.3,5.8Hz,2H).HRMS(ESI + )m / z:527.1799[M+H] +

[0115] Example 21 Preparation of 3-[({4-chloro-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-({[(1r,4r)-4-hydroxycyclohexyl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-21)

[0116] Referring to the method of Example 18, ethanolamine was replaced by trans-p-aminocyclohexanol to obtain a white solid compound YXQ-21. After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, DMSO-d6) δ8.25(s,1H),8.16(d,J=7.4Hz,1H),7.94(d,J=8.0Hz,1H),7.78(q,J=10.3,8.6Hz,2H),7. 73(dd,J=8.4,5.9Hz,2H),7.65–7.61(m,1H),7.59(t,J=7.6Hz,1H),7.55(q,J=6.8,6.1Hz,1H),7.46–7.39(m,2H) ,7.07(d,J=21.9Hz,1H),5.40(d,J=26.0Hz,2H),5.25(d,J=6.0Hz,2H),3.71(s,2H),3.34(dh,J=10.0,6.1,4.6Hz ,1H),2.40(p,J=5.2,4.8Hz,1H),1.84(d,J=10.5Hz,2H),1.77(d,J=10.3Hz,2H),1.08(q,J=12.1Hz,4H).HRMS(ESI +)m / z:567.2127[M+H] +

[0117] Example 22 Preparation of 3-[({4-chloro-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-({[2-(1,4-oxazacyclohexane-4-yl)ethyl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-22)

[0118] Referring to the method of Example 18, ethanolamine was replaced by N-(2-aminoethyl)-morpholine to obtain a white solid compound YXQ-22. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.90–7.84(m,2H),7.54(q,J=3.3,2.6Hz,1H),7.52(d,J=8.1Hz,1H),7.49 (dd,J=8.0,2.7Hz,2H),7.46(dt,J=7.8,1.3Hz,1H),7.42(ddt,J=10.4,8.4,2.3Hz,1H),7.40–7.36(m,2H ),7.33(t,J=7.7Hz,1H),7.30(d,J=7.3Hz,1H),6.45(s,1H),5.17(d,J=9.5Hz,2H),5.00(s,2H),3.91(s ,2H),3.53–3.46(m,4H),2.79(t,J=5.9Hz,2H),2.51(dd,J=6.9,4.9Hz,2H),2.30–2.24(m,4H).HRMS(ESI + )m / z:582.2217[M+H] +

[0119] Example 23 Preparation of 3-[({4-bromo-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(2-hydroxyethyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-23)

[0120] Preparation of compound (VII-3)

[0121] Weigh 5-bromo-2,4-dihydroxybenzaldehyde (521 mg) and NaHCO3 (367 mg), add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 30 minutes, then slowly add compound (Ⅴ-1) (570 mg) and continue to react for 6 hours. After the reaction is completed, remove the acetonitrile solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) several times, and dry the organic phase with anhydrous sodium sulfate and filter to obtain a crude product. The crude product is separated by silica gel chromatography to obtain a white solid compound (Ⅶ-3) (487 mg, 56.16%). After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, Chloroform-d) δ11.41(d,J=8.0Hz,1H),9.69(s,1H),8.06(d,J=1.7Hz,1H),7.97(t,J=8.5Hz,1H),7.72(s,1H),7.61(d,J=8.4H z,1H),7.59(d,J=8.2Hz,1H),7.55(dd,J=8.5,1.7Hz,1H),7.48(t,J=7.7Hz,1H),7.37(t,J=7.5Hz,1H),6.60(s,1H),5.35(d,J=12.5Hz,2H).

[0122] Preparation of compound (X-5)

[0123] Weigh compound (VII-3) (154 mg) and anhydrous K2CO3 (107 mg) in a 100 ml eggplant-shaped bottle, add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 15 minutes, then add 3-bromomethylbenzonitrile (84 mg) and continue to react for 1 hour. After the reaction is completed, remove the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) for several times, and dry the organic phase over anhydrous sodium sulfate and filter to obtain a crude product. Then, purify the crude product by beating in an ice bath with a mixed solvent of ethyl acetate / petroleum ether = 15 / 1, and filter to obtain a white solid compound (X-5) (178 mg, 90.11%). After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, DMSO-d6) δ10.28(s,1H),8.09(m,1H),7.99(m,2H),7.75(d,J=9.2Hz,1H),7.66(d,J=7.9Hz,1H),7.61(pd,J=6.7,4.5Hz,3H ),7.56(m,1H),7.50(td,J=11.4,10.0,4.7Hz,2H),7.39(t,J=7.6Hz,1H),6.72(m,1H),5.42(dd,J=16.8,6.8Hz,2H),5.35–5.23(m,2H).

[0124] Preparation of compound YXQ-23

[0125] Weigh compound (Ⅹ-5) (140 mg) and dissolve it in a mixed solvent of dichloromethane and methanol (4:1, 5 mL), add ethanolamine (0.13 mL) and stir at room temperature for 10 minutes, then add two drops of glacial acetic acid, react at room temperature for 6-8 hours, then add sodium triacetoxyborohydride (232 mg) and continue to react for 12 hours to stop the reaction, evaporate the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 ml) several times, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder and mix well to prepare a sample, separate and purify the crude product by silica gel column chromatography to obtain white solid compound YXQ-23 (105 mg, 68.93%). After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, DMSO-d6) δ8.25(s,1H),8.16(d,J=7.7Hz,1H),7.91(s,1H),7.78(q,J=6.9Hz,2H),7.73(dd,J=8.4,4.5Hz,2H),7.62(d,J=8.5Hz,1H),7 .57(dt,J=15.5,7.8Hz,2H),7.52(s,1H),7.43(t,J=7.5Hz,1H),7.04(s,1 H),5.36(s,2H),5.26(s,2H),3.46(s,2H),2.56(t,J=5.7Hz,2H).HRMS(ESI + )m / z:557.1128[M+H] +

[0126] Example 24 Preparation of 3-[({4-bromo-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(1,3-dihydroxypropan-2-yl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-24)

[0127] Referring to the method of Example 23, ethanolamine was replaced by serinol to obtain a white solid compound YXQ-24. After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ8.25 (s, 1H), 8.16 (d, J = 7.5Hz, 1H), 7.93 (s, 1H), 7. 79(dt,J=14.6,7.3Hz,2H),7.73(dd,J=8.4,4.1Hz,2H),7.66–7.60(m,1H), 7.60–7.52(m,3H),7.43(t,J=7.5Hz,1H),7.04(s,1H),5.36(s,2H),5.26(s ,2H),3.44–3.41(m,2H),3.39–3.35(m,2H),2.59(p,J=5.7Hz,1H).HRMS(ESI + )m / z:587.1176[M+H] +

[0128] Example 25 Preparation of 3-[({4-bromo-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-{[(3-hydroxypropyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-25)

[0129] Referring to the method of Example 23, ethanolamine was replaced by 3-amino-1-propanol to obtain a white solid compound YXQ-25. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,DMSO-d6)δ8.25(d,J=1.7Hz,1H),8.18–8.13(m,1H),7.92(d,J=1.7Hz,1H),7. 81–7.76(m,2H),7.73(dd,J=8.3,4.4Hz,2H),7.62(dd,J=8.5,1.8Hz,1H),7.58(t,J=7.9Hz, 1H),7.57–7.54(m,2H),7.43(td,J=7.5,0.9Hz,1H),7.05(s,1H),5.37(s,2H),5.27(s,2H) ,3.72(s,2H),3.45(d,J=6.1Hz,2H),2.61(t,J=7.0Hz,2H),1.60(p,J=6.6Hz,2H).HRMS(ESI + )m / z:571.1296[M+H] +

[0130] Example 26 Preparation of 3-[({4-bromo-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-({[(1r,4r)-4-hydroxycyclohexyl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-26)

[0131] Referring to the method of Example 23, ethanolamine was replaced by trans-p-aminocyclohexanol to obtain a white solid compound YXQ-26. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,DMSO-d6)δ8.25(s,1H),8.16(d,J=7.7Hz,1H),7.95(s,1H),7.79(dd,J=7.8,3.8H z,2H),7.73(t,J=7.5Hz,2H),7.63(d,J=8.5Hz,1H),7.59(d,J=7.7Hz,1H),7.56(d,J=6.5Hz,2 H),7.43(t,J=7.5Hz,1H),7.06(s,1H),5.38(s,2H),5.25(s,2H),3.73(s,2H),3.36–3.31(m,1 H),2.42(s,1H),1.85(d,J=10.0Hz,2H),1.77(d,J=8.7Hz,2H),1.09(q,J=9.7Hz,4H).HRMS(ESI + )m / z:611.1540[M+H] +

[0132] Example 27 Preparation of 3-[({4-bromo-5-[(dibenzo[1,2-d:1',2'-b]furan-2-ylmethyl)oxy]-2-({[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-27)

[0133] Referring to the method of Example 23, ethanolamine was replaced by trishydroxymethylaminomethane to obtain a white solid compound YXQ-27. After detection and analysis, its spectral data are as follows: 1H NMR(600MHz,DMSO-d6)δ8.24(dd,J=4.5,1.7Hz,1H),8.16(d,J=7.6Hz,1H),7.98–7.89(m,1H) ,7.82(dd,J=20.3,8.0Hz,1H),7.76(d,J=7.9Hz,1H),7.75–7.68(m,2H),7.63–7.59(m,1H),7. 59–7.53(m,2H),7.43(t,J=7.5Hz,1H),7.23–7.11(m,1H),7.06–6.97(m,1H),6.68(d,J=8.2Hz ,1H),5.36(d,J=20.2Hz,2H),5.27(d,J=7.5Hz,2H),3.82–3.68(m,2H),3.47(s,6H).HRMS(ESI + )m / z:617.1282[M+H] +

[0134] Example 28 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]thiophen-2-ylmethyl)oxy]-2-{[(2-hydroxyethyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-28)

[0135] Preparation of compound (III-2)

[0136] Weigh dibenzothiophene (1g), add dichloromethane (10mL) to dissolve, and stir in an ice bath for ten minutes. Add anhydrous TiCl4 (1.5mL) to the above system, then slowly add dichloromethyl methyl ether (1mL) dropwise, and react at room temperature for 4h. After the reaction is completed, quench the reaction with 1mol / LHCl, then wash with saturated NaHCO3 and saturated NaCl solution in turn, extract with dichloromethane (50mL) several times, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder, mix well and prepare samples, separate and purify the crude product by silica gel column chromatography, and obtain orange solid compound (III-2) (0.65g, 56.52%) after purification. After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, Chloroform-d) δ10.15(m,1H),8.41(m,1H),8.15(m,1H),7.94–7.86(m,2H),7.57(m,1H),7.52–7.44(m,2H).

[0137] Preparation of compound (IV-2)

[0138] Weigh compound (III-2) (800 mg) into a 100 mL eggplant-shaped bottle, add methanol (8 mL) to dissolve and stir at 0°C for 15 minutes, then slowly add sodium borohydride (171 mg) and continue to react at 0°C for 30 minutes. After the reaction is completed, pour ice water (10 mL) into the reaction solution and filter to collect a light yellow solid compound (IV-2) (790 mg, 97.82%) (the crude product can be directly used in the next step without further purification). After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ8.15(m,1H),8.08(dd,J=7.1,1.9Hz,1H),7.86(m,1H),7.49–7.43(m,4H),4.96(s,2H).

[0139] Preparation of compound (V-2)

[0140] Weigh compound (Ⅳ-2) (300 mg) into a 50 ml sealed eggplant-shaped bottle, add anhydrous dichloromethane (10 mL) to dissolve, stir at -10 ° C for 30 minutes, slowly add PBr3 (66 μL), and continue to react until there is no raw material left. After the reaction is completed, add water (10 mL) to quench the reaction, and wash with saturated NaHCO3 and saturated NaCl solutions in turn, extract with dichloromethane (30 mL) (repeat 3-5 times), and collect the organic phase. The collected crude product is separated and purified by silica gel chromatography using n-hexane as the eluent to obtain a white powder compound (Ⅴ-2) (262 mg, 67.52%). After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, Chloroform-d) δ8.16(m,1H),8.13(m,1H),7.89(m,1H),7.84(m,1H),7.51–7.43(m,3H),4.77(s,1H),4.68(d,J=29.8Hz,1H).

[0141] Preparation of compound (VII-4)

[0142] Weigh 2,4-dihydroxybenzaldehyde (538g) and anhydrous K2CO3 (898mg), add acetonitrile (20mL) to dissolve, place at 80℃ and stir for 30 minutes, then slowly add compound (Ⅴ-2) (900mg) and continue to react for 3h. After the reaction is completed, remove the acetonitrile solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30mL) several times, dry the organic phase with anhydrous sodium sulfate, and filter to obtain a crude product. The crude product is separated by silica gel chromatography to obtain a white solid compound (Ⅶ-4) (503mg, 46.33%). After detection and analysis, its spectral data are as follows: 1H NMR (600MHz, DMSO-d6) δ11.04(s,1H),10.03(s,1H),8.50–8.46(m,1H),8.39(tdd,J=6.5,4.5,3.6Hz,1H),8.10–8.02(m,2H),7.66(dd,J=8.7 ,2.4Hz,1H),7.63–7.60(m,1H),7.56–7.54(m,1H),7.54–7.53(m,1H),6.71(td,J=8.4,2.3Hz,1H),6.67–6.61(m,1H),5.35(d,J=5.3Hz,2H).

[0143] Preparation of compound (X-6)

[0144] Weigh compound (VII-4) (800 mg) and anhydrous K2CO3 (661 mg) in a 100 ml eggplant-shaped bottle, add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 15 minutes, then add 3-bromomethylbenzonitrile (469 mg) and continue to react for 1 hour. After the reaction is completed, remove the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) for several times, and dry the organic phase over anhydrous sodium sulfate and filter to obtain a crude product. Then, use a mixed solvent of ethyl acetate / petroleum ether = 15 / 1 to purify the crude product by beating in an ice bath, and filter to obtain a milky white solid compound (X-6) (848 mg, 78.85%). After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ10.35(d,J=11.4Hz,1H),8.20–8.17(m,1H),8.16(tt, J=4.8,1.9Hz,1H),7.89(s,1H),7.88(d,J=2.8Hz,1H),7.85(d,J=9.1Hz,1H),7.69( d,J=1.9Hz,1H),7.65(d,J=7.9Hz,1H),7.60(dt,J=7.9,2.9Hz,1H),7.52–7.45(m,4 H),6.78–6.70(m,1H),6.59–6.53(m,1H),5.31–5.24(m,2H),5.12(d,J=36.3Hz,2H).

[0145] Preparation of compound YXQ-28

[0146] Weigh compound (Ⅹ-6) (150 mg) and dissolve it in a mixed solvent of dichloromethane and methanol (4:1, 5 mL), add ethanolamine (161 μL) and stir at room temperature for 10 minutes, then add two drops of glacial acetic acid, react at room temperature for 6-8 hours, then add sodium triacetoxyborohydride (283 mg) and continue to react for 12 hours to stop the reaction, evaporate the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 ml) several times, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder and mix well to prepare a sample, separate and purify the crude product by silica gel column chromatography to obtain a light yellow viscous compound YXQ-28 (55 mg, 33.3%). After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ8.13–8.03(m,2H),7.82–7.75(m,1H),7.65–7.5 7(m,1H),7.57–7.52(m,1H),7.52–7.46(m,1H),7.44–7.32(m,4H),7.25–7.20( m,1H),6.60–6.53(m,1H),6.51–6.45(m,1H),5.23(s,4H),4.00(d,J=11.0Hz, 2H),3.65(tt,J=10.8,4.6Hz,2H),2.86(td,J=10.7,9.3,6.0Hz,2H).HRMS(ESI + )m / z:495.1814[M+H] +

[0147] Example 29 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]thiophen-2-ylmethyl)oxy]-2-({[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino}methyl)phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-29)

[0148] Referring to the method of Example 28, ethanolamine was replaced by trishydroxymethylaminomethane to obtain a white solid compound YXQ-29. After detection and analysis, its spectral data are as follows: 1H NMR(600MHz,Chloroform-d)δ7.99–7.85(m,2H),7.72–7.59(m,2H),7.55(d,J=25.6Hz,1H),7.46(dd,J=19.9,7.8Hz,1H),7.33–7.20(m,6 H),6.45(t,J=9.3Hz,1H),6.42–6.35(m,1H),5.00(s,2H),4.88(d,J=9.6Hz,2H),3.98(d,J=18.3Hz,2H),3.47(d,J=9.4Hz,6H).HRMS(ESI + )m / z:555.2020[M+H] +

[0149] Example 30 Preparation of 3-[({5-[(dibenzo[1,2-d:1',2'-b]thiophen-2-ylmethyl)oxy]-2-{[(3-hydroxypropyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-30)

[0150] Referring to the method of Example 28, ethanolamine was replaced by 3-amino-1-propanol to obtain a yellow viscous compound YXQ-30. After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,Chloroform-d)δ8.11–8.01(m,2H),7.81–7.67(m,2H),7.60–7.57(m,1H),7. 49–7.44(m,1H),7.38(tdd,J=12.3,7.0,2.6Hz,4H),7.36–7.31(m,1H),7.28(t,J=8.8Hz, 1H),6.61–6.52(m,1H),6.50–6.42(m,1H),5.20(d,J=25.3Hz,1H),5.05(d,J=21.2Hz,3H) ,3.99–3.92(m,2H),3.64–3.52(m,2H),3.00–2.87(m,2H),1.76(h,J=5.4Hz,2H).HRMS(ESI + )m / z:509.1965[M+H] +

[0151] Example 31 Preparation of 3-[({4-chloro-5-[(dibenzo[1,2-d:1',2'-b]thiophen-2-ylmethyl)oxy]-2-{[(2-hydroxyethyl)amino]methyl}phenyl}oxy)methyl]benzene-1-carbonitrile (YXQ-31)

[0152] Preparation of compound (VII-5)

[0153] Weigh 5-chloro-2,4-dihydroxybenzaldehyde (150 mg) and NaHCO3 (121 mg), add acetonitrile (20 mL) to dissolve, place at 80 ° C and stir for 30 minutes, then slowly add compound (Ⅴ-2) (200 mg) and continue to react for 3 hours. After the reaction is completed, remove the acetonitrile solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) several times, and dry the organic phase with anhydrous sodium sulfate and filter to obtain a crude product. The crude product is separated by silica gel chromatography to obtain a white solid compound (Ⅶ-5) (134 mg, 50.35%). After detection and analysis, its spectral data are as follows: 1 H NMR(600MHz,DMSO-d6)δ11.16(s,1H),10.04(d,J=4.8Hz,1H),8.50–8.42(m,1H),8.42–8.34(m,1H),8.12–8.05 (m,1H),7.74–7.67(m,2H),7.66–7.58(m,1H),7.58–7.51(m,2H),6.87(d,J=5.9Hz,1H),5.51(d,J=80.9Hz,2H).

[0154] Preparation of compound (X-7)

[0155] Weigh compound (Ⅶ-5) (96 mg) and anhydrous K2CO3 (72 mg) in a 100 ml eggplant-shaped bottle, add acetonitrile (10 mL) to dissolve, place at 80 ° C and stir for 15 minutes, then add 3-bromomethylbenzonitrile (87 mg) and continue to react for 1 hour. After the reaction is completed, remove the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 mL) for several times, and dry the organic phase over anhydrous sodium sulfate and filter to obtain a crude product. Then, use a mixed solvent of ethyl acetate / petroleum ether = 15 / 1 to purify the crude product by beating in an ice bath, and filter to obtain a milky white solid compound (Ⅹ-7) (105 mg, 83.35%). After detection and analysis, its spectral data are as follows: 1HNMR(600MHz,DMSO-d6)δ10.23(d,J=2.7Hz,1H),8.51(s,1H),8.42(dd,J=7.2,2.9H z,1H),8.39–8.33(m,1H),8.08–8.04(m,1H),8.01(d,J=5.2Hz,1H),7.86–7.77(m,2H ),7.74–7.70(m,1H),7.66–7.62(m,1H),7.62–7.58(m,1H),7.55(tdd,J=7.2,6.1,5 .1,3.4Hz,2H),7.28(d,J=8.4Hz,1H),5.60(d,J=72.3Hz,2H),5.43(d,J=6.4Hz,2H).

[0156] Preparation of compound YXQ-31

[0157] Weigh compound (Ⅹ-7) (324 mg) and dissolve it in a mixed solvent of dichloromethane and methanol (4:1, 10 mL), add ethanolamine (0.3 mL) and stir at room temperature for 10 minutes, then add two drops of glacial acetic acid, react at room temperature for 6-8 hours, then add sodium triacetoxyborohydride (568 mg) and continue to react for 12 hours to stop the reaction, evaporate the solvent under reduced pressure, wash with water and saturated NaCl solution in turn, extract with dichloromethane (30 ml) several times, dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, add appropriate amount of silica gel powder and mix well to prepare a sample, separate and purify the crude product by silica gel column chromatography to obtain white solid compound YXQ-31 (281 mg, 79.34%). After detection and analysis, its spectral data are as follows: 1 H NMR (600MHz, DMSO-d6) δ8.50–8.30(m,2H),8.08–8.04(m,1H),7.94–7.89(m,1H),7.78( tdd,J=11.8,10.3,9.3,3.3Hz,2H),7.73–7.65(m,1H),7.62–7.59(m,1H),7.59–7.56(m, 1H),7.56–7.52(m,2H),7.41(d,J=2.4Hz,1H),7.11–7.04(m,1H),5.53–5.37(m,2H),5. 25(d,J=9.4Hz,2H),3.73(s,2H),3.48(t,J=5.8Hz,2H),2.60(t,J=5.7Hz,2H).HRMS(ESI + )m / z:529.1417[M+H] +

[0158] Example 32 Cytotoxicity Evaluation

[0159] (1) Experimental principle: The MTT experiment is a common method for testing cell activity. It mainly uses the principle that succinate dehydrogenase in the mitochondria of living cells can reduce water-soluble tetrasulfobiphenylthiazol blue (MTT) to water-insoluble purple-red methylthiazole salt. This salt will be deposited in the cell in the form of crystals, while dead cells do not have this ability. Dimethyl sulfoxide (DMSO) can dissolve the purple-red crystals in living cells, and the absorbance can be detected at a wavelength of 490nm by an enzyme reader. Within a certain range of cell numbers, the luminescence detected by the enzyme reader (i.e., the amount of thiazole salt crystals in living cells) is proportional to the number of cells. The cell survival rate can be evaluated based on the absorbance value measured by the enzyme reader (colorimetric method).

[0160] (2) Experimental method: Tumor cells in the logarithmic growth phase were inoculated into 96-well plates, with 10,000, 4,000 and 15,000 HCC1937 cells, HeLa cells and HepG2 cells in each well, respectively. 100 μL of culture medium containing cell fluid was added to each well, and 3 replicates were added to each group. After 24 hours of cell culture, drugs were administered. The positive drug compound BMS-202 and the test compound were prepared into a 50 mM stock solution with DMSO. An appropriate amount of the stock solution was diluted to 1 μM with culture medium and administered at 150 μL / well. 150 μL of culture medium containing cell fluid was added to the negative control group, and 150 μL of culture medium without cell fluid was added to the blank group. The cells were cultured in the incubator for 48 hours. After 48 hours, 10 μL of MTT solution (5 μg / L) was added to each well, incubated at 37°C for 4 hours, the MTT solution was discarded and 150 μL of DMSO was added to each well. The OD value at a wavelength of 490 nm was detected using an enzyme-labeled instrument.

[0161] The cell survival rate calculation formula is:

[0162] [(OD value 实验组 -OD value 空白组 ) / (OD value 对照组 -OD value 空白组 )]×100%

[0163] (3) Experimental results:

[0164] Table 1. Survival rate of each cell line after administration of 1 μM concentration of compound for 48 h

[0165]

[0166]

[0167] The results of the MTT experiment (Table 1) showed that the compounds of the examples showed lower toxicity than the positive compound BMS-202 at the cellular level.

[0168] Example 33 PD-1 / PD-L1 binding inhibitory activity test

[0169] (1) Experimental principle: The Human PD1 / PD-L1 Kit is used to detect the binding of PD-1 and PD-L1, and can be used to quickly and high-throughput screen inhibitors of PD-1 and PD-L1. The kit contains two proteins, Tag1-PD-1 and Tag2-PD-L1, and two antibodies, namely: Anti-Tag1 (labeled with fluorescent donor Eu, Anti-Tag1-Eu); Anti-Tag2 (labeled with fluorescent receptor A2, Anti-Tag2-A2). When PD-1 and PD-L1 bind, Anti-Tag1-Eu and Anti-Tag2-A2 are close to each other, and fluorescence resonance energy transfer (FRET) can occur. Eu is excited by 320nm excitation light, and the donor emits 620nm light. This 620nm light excites the fluorescent receptor A2, and the receptor emits 665nm light. Adding the corresponding active inhibitor will block the interaction between PD-1 / PD-L1 and thus destroy the FRET formation. The inhibition intensity is inversely proportional to the FRET signal (665 / 620).

[0170] (2) Experimental method: Accurately weigh 1 mg of each compound YXQ-1 to YXQ-31, dilute it with DMSO to a sample with an intermediate concentration of 2 μM / L, and then use the diluent in the kit to dilute the sample with an intermediate concentration of 2 μM / L to a final concentration of 1 μM / L; add 4 μL of the diluted test compound sample to a 96-well plate, and do not add samples to the positive / negative control groups; after mixing, add 4 μL PD-1 in turn, mix again, and then add 4 μL PD-L1 and incubate at 37°C for 15 minutes (no addition to the positive control group, but addition to the negative control group); mix Anti-Tag1 and Anti-Tag2 at a volume ratio of 1:1, then add 8 μL to each well and shake evenly, then add 12 μL of diluent buffer to each well and mix; incubate at 37°C for 2 hours, and use the HTRF module of the microplate reader to detect the fluorescence values ​​of each well at 665nm and 620nm. The inhibition rate calculation formula of each example compound is:

[0171] Inhibition rate % = (OD value 阳性对照孔 -OD value 药物孔 ) / (OD value 阳性对照孔 -OD value 阴性对照孔 )*100%

[0172] (3) Experimental results:

[0173] Table 2. Inhibition rate of each compound at 1 μM concentration

[0174]

[0175]

[0176] The results of the PD-1 / PD-L1 binding inhibitory activity test showed that the inhibition rate of the compound in Example 1 on PD-L1 reached 49%, which can block the binding of PD-L1 and PD-1 at the molecular level, and has the potential for further research and development and modification.

Claims

1. benzyl phenyl ether compound, characterized in that A compound conforming to the following general formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or hydrate thereof; in, X is O, S; R 1 H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl, or C substituted with H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl 1-10 Saturated / unsaturated alkyl or heteroalkyl, C 3-10 Saturated / unsaturated cycloalkyl or heterocycloalkyl; R 2 H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl, or C substituted with H, F, Cl, Br, I, CN, CF3, CF2CF3, OH, SH, NH2, NO2, OCH3, OCF3, OCF2CF3, alkenyl, alkynyl 1-10 Saturated / unsaturated alkyl or heteroalkyl, C 3-10 Saturated / unsaturated cycloalkyl or heterocycloalkyl; R 3 C 1-10 Alkyl or heteroalkyl, C 3-10 Cycloalkyl or heterocycloalkyl, benzene ring, condensed aromatic ring, aromatic heterocycle, benzoheterocycle, aromatic heterocycle-conjugated cycloalkyl; R 4 Any of the following groups:

2. benzyl phenyl ether compound according to claim 1, characterised in that The following compounds YXQ-1~YXQ-31 one:

3. The benzyl phenyl ether compound according to claim 1, characterized in that: The pharmaceutically acceptable salts include salts formed between the compound of formula I and acids, metal ions, pharmaceutically acceptable amines, ammonium ions or choline.

4. The benzyl phenyl ether compound according to claim 3, characterized in that: The acid is galactaric acid, D-glucuronic acid, glycerophosphoric acid, hippuric acid, isethionic acid, lactobionic acid, maleic acid, 1,5-naphthalenedisulfonic acid, naphthalene-2-sulfonic acid, pivalic acid, terephthalic acid, thiocyanic acid, bile acid, n-dodecylsulfuric acid, benzenesulfonic acid, citric acid, D-glucose, glycolic acid, lactic acid, malic acid, malonic acid, mandelic acid, phosphoric acid, propionic acid, hydrochloric acid, sulfuric acid, tartaric acid, succinic acid, formic acid, hydroiodic acid, hydrobromic acid, methanesulfonic acid, nicotinic acid, nitric acid, orotic acid, oxalic acid, picric acid, L-pyroglutamic acid, saccharinic acid, salicylic acid, gentisic acid, p-toluenesulfonic acid, valeric acid, palmitic acid, sebacic acid, stearic acid, lauric acid, acetic acid, adipic acid, carbonic acid, 4-benzenesulfonic acid, ethanedisulfonic acid, ethylsuccinic acid, fumaric acid, 3-hydroxynaphthalene-2-carboxylic acid, 1-hydroxynaphthalene-2-carboxylic acid, oleic acid, undecylenic acid, ascorbic acid, camphoric acid, camphorsulfonic acid, dichloroacetic acid, ethanesulfonic acid; the metal ions are sodium, potassium, and calcium ions; the pharmaceutically acceptable amines are ethylenediamine and tromethamine.

5. Use of the benzyl phenyl ether compound according to claim 1 in the preparation of drugs for diseases related to the PD-1 / PD-L1 signaling pathway.

6. The use according to claim 5, characterized in that: The diseases related to the PD-1 / PD-L1 signaling pathway are malignant tumors, autoimmune diseases, organ transplant rejection, infectious diseases, and inflammatory diseases; and the drug is a PD-1 / PD-L1 inhibitor.

7. The use according to claim 6, characterized in that: The malignant tumor is breast cancer, cervical cancer, liver cancer, non-small cell carcinoma, ovarian cancer, Merkel cell carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, bladder cancer, colorectal cancer, pancreatic cancer, peritoneal cancer, glioma, glioblastoma, melanoma, prostate cancer, lymphoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, gastrointestinal stromal tumor, thyroid cancer, bile duct cancer, endometrial cancer, fallopian tube cancer, renal cell carcinoma, anaplastic large cell lymphoma, acute myeloid leukemia and multiple myeloma; the autoimmune disease is Chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, systemic lupus erythematosus, autoimmune hemolytic anemia, rheumatoid arthritis, ulcerative colitis and Crohn's disease; the organ transplantation is liver transplantation, bone marrow transplantation, kidney transplantation, heart transplantation; the infectious diseases are bacterial and viral infections; the inflammatory diseases are acute idiopathic polyneuritis, non-alcoholic fatty hepatitis, pneumonia, emphysema, rhinitis, myocarditis, neurodermatitis, tracheitis, respiratory distress syndrome, chronic obstructive pulmonary disease.

8. The method for preparing the benzyl phenyl ether compound according to claim 1, characterized in that Proceed according to the following reaction route: wherein Y is fluorine, chlorine, bromine, iodine, methanesulfonate, p-toluenesulfonate or trifluoromethanesulfonate.

9. The preparation method according to claim 8, characterized in that The following steps are involved: <1> Compound (II) is subjected to formylation reaction under the action of Lewis acid to prepare compound (III); <2> Compound (IV) is prepared by reduction reaction of compound (III); <3> The compound (V) is prepared by halogenation reaction of the compound (IV); <4> Compound (VII) is prepared by reacting compound (V) with compound (VI) under alkaline conditions through a nucleophilic substitution reaction; <5> Compound (X) is prepared by reacting compound (VII) with compound (VIII) under alkaline conditions through a nucleophilic substitution reaction; <6> Compound (IX) can be prepared by reductive amination reaction of compound (X) with compound (IX).

10. The preparation method according to claim 9, characterized in that: step <1> wherein the Lewis acid is anhydrous SnCl4, TiCl4, AlCl3, POCl3; the formylation reagent used in the formylation is 1,1-dichloromethyl methyl ether, N,N-dimethyl methyl ether; the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide; and the reaction temperature is room temperature; step <2> In the reduction reaction, the reducing agent used is sodium borohydride or potassium borohydride, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is -20°C to room temperature; step <3> In the halogenation reaction, the halogenating agent used is PBr3, CBr4, HBr, SOCl2, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is -20°C to room temperature; step <4> In the nucleophilic substitution reaction, the base used is sodium cyanide, potassium carbonate, sodium carbonate, cesium carbonate, sodium bicarbonate, triethylamine, diisopropylethylamine, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is 60°C-80°C; step <5> In the nucleophilic substitution reaction, the base used is sodium cyanide, potassium carbonate, sodium carbonate, cesium carbonate, sodium bicarbonate, triethylamine, diisopropylethylamine, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, and the reaction temperature is 60°C-80°C; step <6> In the reductive amination reaction, the reducing agent used is sodium borohydride, sodium triacetoxyborohydride or cyanoborohydride, the reaction solvent is n-hexane, cyclohexane, benzene, toluene, chloroform, dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether, ethyl acetate, methanol, ethanol, acetone, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dimethyl sulfoxide or a combination thereof; the reaction temperature is room temperature.

Citation Information

Patent Citations

  • Benzylphenylate derivative and preparation method thereof, pharmaceutical composition and application

    CN107417572A

  • Nitrophenyl ether compounds, and preparation methods, pharmaceutical compositions and application thereof

    CN111187172A

  • Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof

    US20130022629A1